Skip to main content
. 2019 May;16(2):234–246. doi: 10.20892/j.issn.2095-3941.2018.0284

2.

Confirmation of radiosensitisation by olaparib in BRAF mutant and WT RKO cells by: (A) Long-term cell proliferation assays, showing separation (red arrows) between IC<sub>50</sub> curves normalised for radiation effect, indicating significant radiosensitisation (BRAF-mutant: <italic>P</italic> ≤ 0.001; BRAF-WT: <italic>P</italic> ≤ 0.01, calculated by paired <italic>t</italic>-test). (B) Clonogenic survival assays, showing significant radiation enhancement by 0.1–1 μM olaparib at 1% cell survival (BRAF-mutant: <italic>P</italic> ≤ 0.05; BRAF-WT: <italic>P</italic> ≤ 0.001), calculated by one-way ANOVA in multiple comparison tests). Data show the mean of <italic>n</italic> = 3 experiments ± SEM (*<italic>P</italic> ≤ 0.05, **<italic>P</italic> ≤ 0.01, ***<italic>P</italic> ≤ 0.001).

Validation of radiosensitisation effects of olaparib in BRAF-mutant and BRAF-WT isogenic CRC cells.